Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

KX2-391

Catalog No: tcsc0248

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
897016-82-9

Formula:
$C_{26}H_{29}N_3O_3$

Pathway:
Protein Tyrosine Kinase/RTK;Cell Cycle/DNA Damage;Cytoskeleton

Target:
Src;Microtubule/Tubulin;Microtubule/Tubulin

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Alternative Names:
KX-01

Observed Molecular Weight:
431.53

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

KX2-391 is an inhibitor of **Src** that targets the peptide substrate site of Src, with **GI_{50}** of 9-60 nM in cancer cell lines.

IC50 & Target: GI50: 9 nM (Src, in HuH7 cells), 13 nM (Src, in PLC/PRF/5 cells), 26 nM (Src, in Hep3B cells), 60 nM (Src, in HepG2 cells) [1]

In Vitro: KX2-391 is a Src inhibitor that is directed to the Src substrate pocket. KX2-391 shows steep dose-response curves against Huh7 (GI_{50}=9 nM), PLC/PRF/5 (GI_{50}=13 nM), Hep3B (GI_{50}=26 nM), and HepG2 (GI_{50}=60 nM), four hepatic cell cancer (HCC) cell lines [1]. KX2-391 is found to inhibit certain leukemia cells that are resistant to current commercially available drugs, such as those derived from chronic leukemia cells with the T3151 mutation. KX2-391 is evaluated in engineered Src driven cell growth assays inNIH3T3/c-Src527F and SYF/c-Src527F cells and exhibits GI_{50} with 23 nM and 39 nM, respectively[2].

In Vivo: Orally administered KX2-391 is shown to inhibit primary tumor growth and to suppress metastasis, in pre-clinical animal models of cancer[2].